Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of RT-Led Daily Adaptive Radiotherapy for Submandibular Gland-Sparing in Head and Neck Cancer (RTL-DART)

NCT07348887 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT07348887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of RT-Led Daily Adaptive Radiotherapy for Submandibular Gland-Sparing in Head and Neck Cancer (RTL-DART)
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Recruiting
Start date
October 15, 2025
Completion date
October 1, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell cancer of head and neck (scchn)